NCM
SMMT icon

NEXTBio Capital Management’s Summit Therapeutics SMMT Stock Holding History

NEXTBio Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-89,717
Closed -$1.7M – 26
2026
Q1 		$1.7M Buy
+89,717
New +$1.45M 0.79% 23

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

NEXTBio Capital Management's SMMT Position: Q2 2026 in Review

NEXTBio Capital Management sold out of Summit Therapeutics (SMMT) in Q2 2026, closing a stake of 89,717 shares — an estimated $1.7M sold.

NEXTBio Capital Management first reported a position in SMMT in Q1 2026 and held it in 1 quarter. The position peaked at $1.7M in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • NEXTBio Capital Management reported no remaining Summit Therapeutics position as of Q2 2026 after selling out during the quarter.
  • NEXTBio Capital Management sold 89,717 Summit Therapeutics shares in Q2 2026, an estimated $1.7M.
  • NEXTBio Capital Management first reported a position in Summit Therapeutics in Q1 2026 and held it in 1 quarter.
  • NEXTBio Capital Management's Summit Therapeutics position peaked at $1.7M in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on NEXTBio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.